platinum has been researched along with amrubicin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Benedetti, F; Cortinovis, D; Galetta, D; Inoue, A; Kubota, K; Makris, L; Niho, S; Nishio, M; Satouchi, M; Scagliotti, G; Valmadre, G; Yoshihara, E | 1 |
| Fujisawa, M; Jimbo, N; Kimbara, S; Minami, H; Nakano, Y; Suzuki, K; Terakawa, T; Toyoda, M | 1 |
| Funasaka, C; Kageyama, A; Kanemasa, Y; Omuro, Y; Shimoyama, T | 1 |
1 trial(s) available for platinum and amrubicin
| Article | Year |
|---|---|
A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Platinum; Pyrrolidines; Small Cell Lung Carcinoma; Thymine; Topotecan; Treatment Outcome; Trifluridine; Uracil | 2016 |
2 other study(ies) available for platinum and amrubicin
| Article | Year |
|---|---|
Amrubicin for Patients With Platinum-refractory Small-cell Prostate Cancer: Two Case Reports.
Topics: Aged; Anthracyclines; Antineoplastic Agents; Carcinoma, Small Cell; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Platinum; Prognosis; Prostatic Neoplasms | 2020 |
[Efficacy of Amrubicin Monotherapy for Patients with Extrapulmonary Neuroendocrine Carcinomas Refractory to Platinum-Based Chemotherapy].
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Treatment Outcome | 2020 |